GO:0004056 argininosuccinate lyase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004056 (argininosuccinate lyase activity) catalyzes the reversible cleavage of N-(L-arginino)succinate into fumarate and L-arginine, the fourth step of the urea cycle and the final step of arginine biosynthesis.
• The enzyme is a homotetramer; in humans it is encoded by ASL, and inherited ASL deficiency causes argininosuccinic aciduria, a urea cycle disorder with hyperammonemia and multi-system complications.
• Beyond the canonical forward reaction, ASL can operate in reverse (fumarate + arginine to argininosuccinate) in fumarate hydratase-deficient cancer cells, linking the enzyme to oncometabolite-driven metabolic rewiring.
• ASL is a moonlighting protein: it supplies arginine for nitric oxide synthesis, interacts with TERT promoter machinery in glioblastoma, and is regulated by lysine acetylation [3,5,6].
• Duck delta2-crystallin is a lens structural protein that retains endogenous argininosuccinate lyase activity, providing a classic model for mechanistic and kinetic studies of the enzyme [7,8].
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of ASL function in urea cycle flux, tumor metabolism and TERT activation [4,5].
Description
Argininosuccinate lyase activity (GO:0004056) is a molecular function defined by the reaction N-(L-arginino)succinate = fumarate + L-arginine. This reaction is the fourth enzymatic step of the urea cycle and the terminal step of arginine biosynthesis, making it a central node in nitrogen disposal and arginine homeostasis. The enzyme is conserved across eukaryotes and prokaryotes, and its catalytic chemistry has been studied in detail using the duck lens delta2-crystallin, which is a bifunctional protein with both structural and enzymatic roles [7,8]. In humans, loss-of-function variants in ASL cause argininosuccinic aciduria, the second most common urea cycle disorder, characterized by hyperammonemia, elevated argininosuccinate, and long-term neurocognitive and hepatic complications. Beyond inherited disease, recent work has shown that ASL activity can be reversed in fumarate hydratase-deficient cancers, where accumulated fumarate drives the reverse reaction to consume arginine and produce argininosuccinate. ASL also contributes to arginine-dependent signaling, including nitric oxide production and TERT promoter activation in glioblastoma [5,6]. Because arginine is a conditionally essential amino acid for tumors and immune cells, understanding ASL regulation has broad implications for cancer metabolism and therapy [1,6]. This article summarizes the definition, mechanism, key genes, disease links and research methods for GO:0004056, with a focus on CRISPR-based models for functional validation.
argininosuccinate lyase activity At A Glance
| GO ID | GO:0004056 |
|---|---|
| GO term | argininosuccinate lyase activity |
| Ontology | molecular_function |
| Synonym | argininosuccinase activity; arginine-succinate lyase activity; N-(L-argininosuccinate) arginine-lyase activity; omega-N-(L-arginino)succinate arginine-lyase activity |
| Major function | Catalyzes the reversible cleavage of N-(L-arginino)succinate to fumarate and L-arginine, the fourth step of the urea cycle and the final step of arginine biosynthesis. |
| Enzyme class | Lyase (EC 4.3.2.1), carbon-nitrogen lyase |
| Substrate | N-(L-arginino)succinate (argininosuccinate) |
| Products | Fumarate and L-arginine |
| Cofactors | None required; the reaction proceeds via a carbanion intermediate and general acid-base catalysis. |
| Human gene | ASL (argininosuccinate lyase) |
| Subcellular location | Cytosol (urea cycle enzymes are cytosolic except CPS1 and OTC, which are mitochondrial) |
What Is GO:0004056?
GO:0004056 describes the catalytic activity of argininosuccinate lyase, which converts N-(L-arginino)succinate (argininosuccinate) into fumarate and L-arginine. The reaction is reversible and belongs to the lyase class, specifically a carbon-nitrogen lyase that eliminates fumarate from the substrate. The official definition is: Catalysis of the reaction: N-(L-arginino)succinate = fumarate + L-arginine. Synonyms include argininosuccinase activity, arginine-succinate lyase activity, and omega-N-(L-arginino)succinate arginine-lyase activity. The enzyme is a homotetramer in most organisms, and in humans it is encoded by the ASL gene. The activity is essential for the urea cycle and for arginine biosynthesis in organisms that produce arginine.
Why Is argininosuccinate lyase activity Important in Cell Biology?
Argininosuccinate lyase activity is essential for nitrogen detoxification and arginine homeostasis. In humans, biallelic ASL mutations cause argininosuccinic aciduria, a urea cycle disorder with hyperammonemia, elevated plasma argininosuccinate, and risk of neurocognitive deficits, hepatic fibrosis and hypertension. The enzyme also supplies arginine for nitric oxide synthesis and protein synthesis, and its reverse activity in fumarate hydratase-deficient tumors links it to oncometabolite-driven metabolic reprogramming [4,6]. In glioblastoma, ASL contributes to mutant TERT promoter activation, highlighting a non-canonical role in transcriptional regulation. Because arginine is critical for tumor growth and immune function, ASL is a potential target for metabolic therapies [1,6]. Studying GO:0004056 therefore spans inherited metabolic disease, cancer metabolism and cell signaling.
• Urea cycle: ASL catalyzes the fourth step, producing arginine and fumarate, which feeds into the TCA cycle.
• Arginine biosynthesis: In organisms that synthesize arginine, ASL is the final enzyme of the pathway.
• Disease: ASL deficiency causes argininosuccinic aciduria, with hyperammonemia and multi-organ complications.
• Cancer metabolism: Reverse ASL activity in FH-deficient cells consumes arginine and produces argininosuccinate, linking to fumarate-driven tumorigenesis.
• TERT regulation: ASL drives activation of mutant TERT promoter in glioblastoma, connecting metabolism to telomerase regulation.
• Nitric oxide signaling: ASL provides arginine for NO synthesis, affecting vascular and immune functions.
• Acetylation: ASL is regulated by lysine acetylation, which can alter its enzymatic activity.
• Model system: Duck delta2-crystallin is a bifunctional enzyme with ASL activity, useful for mechanistic studies [7,8].
• Therapeutic target: ASL is being explored as a target in arginine-dependent cancers [1,6].
• CRISPR modeling: Knockout and point-mutation models allow precise dissection of ASL function in vivo and in vitro [4,5].
What Happens During argininosuccinate lyase activity?
Substrate binding and orientation
In simple terms: The enzyme grabs its substrate, argininosuccinate, and positions it for cleavage.
Argininosuccinate lyase binds N-(L-arginino)succinate in its active site, which is formed at the interface of subunits in the homotetramer. The substrate is oriented so that the carbon-nitrogen bond between the arginine moiety and the succinate moiety is exposed to catalytic residues. The enzyme uses a general acid-base mechanism, with a conserved histidine and other residues participating in proton transfer. The binding is specific for the L-arginino configuration, as indicated by the synonym omega-N-(L-arginino)succinate arginine-lyase activity.
Catalytic cleavage and product release
In simple terms: The enzyme breaks the substrate into fumarate and arginine, which are then released.
The cleavage reaction proceeds via a carbanion intermediate, resulting in the elimination of fumarate and the formation of L-arginine. The reaction is reversible, and the equilibrium can favor either direction depending on substrate and product concentrations. In the forward direction, fumarate enters the TCA cycle and arginine is used for protein synthesis or nitric oxide production. In the reverse direction, as seen in fumarate hydratase-deficient cells, fumarate and arginine combine to form argininosuccinate, consuming arginine.
Role in the urea cycle
In simple terms: This reaction is one of the steps that convert toxic ammonia into urea for excretion.
In the urea cycle, argininosuccinate lyase acts after argininosuccinate synthetase, which condenses citrulline and aspartate to form argininosuccinate. ASL then cleaves argininosuccinate to arginine and fumarate. Arginine is subsequently hydrolyzed by arginase to urea and ornithine, completing the cycle. Defects in ASL cause accumulation of argininosuccinate and hyperammonemia, the hallmark of argininosuccinic aciduria.
Moonlighting functions and regulation
In simple terms: The enzyme has additional jobs beyond the urea cycle, including helping control gene activity and responding to metabolic signals.
ASL is not just a metabolic enzyme; it interacts with other proteins and participates in signaling. In glioblastoma, ASL is involved in activating the mutant TERT promoter, linking metabolism to telomerase regulation. ASL activity can be modulated by lysine acetylation, which may affect its catalytic efficiency. Additionally, ASL provides arginine for nitric oxide synthesis, influencing vascular tone and immune responses. These moonlighting functions expand the importance of GO:0004056 beyond classical metabolism.
Key Genes Involved in GO:0004056 argininosuccinate lyase activity
The following genes and proteins are directly or indirectly associated with argininosuccinate lyase activity, including the enzyme itself, urea cycle partners, and regulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ASL | Encodes argininosuccinate lyase, the enzyme that catalyzes the reaction | Mutations cause argininosuccinic aciduria; target for cancer metabolism studies [2,4] |
| ASS1 | Argininosuccinate synthetase, produces argininosuccinate for ASL | Deficiency causes citrullinemia; often co-regulated with ASL in cancer [1,6] |
| ARG1 | Arginase, hydrolyzes arginine to urea and ornithine | Completes urea cycle; competes with ASL for arginine |
| OTC | Ornithine transcarbamylase, earlier urea cycle enzyme | Deficiency causes hyperammonemia; model for urea cycle disorders |
| CPS1 | Carbamoyl phosphate synthetase 1, first urea cycle enzyme | Regulates flux into the cycle; target for metabolic engineering |
| FH | Fumarate hydratase, converts fumarate to malate | Deficiency leads to fumarate accumulation and reverse ASL activity |
| TERT | Telomerase reverse transcriptase | Mutant promoter activation in glioblastoma involves ASL |
| NOS1 | Neuronal nitric oxide synthase | Uses arginine produced by ASL for NO synthesis |
| NOS2 | Inducible nitric oxide synthase | Arginine supply from ASL affects immune response |
| NOS3 | Endothelial nitric oxide synthase | Vascular function depends on arginine from ASL |
| SIRT1 | NAD-dependent deacetylase | May regulate ASL acetylation status |
| EP300 | Histone acetyltransferase p300 | Can acetylate metabolic enzymes including ASL |
| MYC | Oncogenic transcription factor | Drives expression of arginine metabolism genes |
| HIF1A | Hypoxia-inducible factor 1-alpha | Regulates metabolic adaptation, may influence ASL expression |
| KEAP1 | Kelch-like ECH-associated protein 1 | Mutated in cancers, linked to metabolic stress |
| NFE2L2 | Nrf2, antioxidant response transcription factor | May modulate ASL expression under oxidative stress |
| GLS | Glutaminase | Provides glutamate for arginine synthesis, indirectly affects ASL |
| PYCR1 | Pyrroline-5-carboxylate reductase 1 | Proline synthesis competes with arginine pathway |
How Is argininosuccinate lyase activity Regulated?
Argininosuccinate lyase activity is regulated at multiple levels. Transcriptionally, ASL expression can be induced by substrate availability and hormones, although specific transcription factors are not fully defined. Post-translationally, ASL is subject to lysine acetylation, which can alter its enzymatic activity; a study identified ASL as an acetylated protein, suggesting regulation by acetyltransferases and deacetylases. In cancer, ASL expression is often dysregulated; for example, in glioblastoma, ASL contributes to mutant TERT promoter activation, indicating a role in transcriptional regulation. Metabolically, the reverse reaction is favored when fumarate accumulates, as in FH-deficient tumors, providing a feedback mechanism. Additionally, arginine availability can affect ASL flux through the urea cycle and nitric oxide synthesis.
argininosuccinate lyase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ASL | Argininosuccinic aciduria | ASL knockout mouse; patient-derived iPSCs; knock-in of patient mutations |
| ASL | Glioblastoma (TERT promoter activation) | ASL knockout in glioblastoma cell lines; TERT promoter reporter assays |
| FH | Hereditary leiomyomatosis and renal cell cancer (HLRCC) | FH-deficient cell lines; ASL reverse activity assays |
| ASS1 | Citrullinemia type I | ASS1 knockout hepatocytes; urea cycle flux measurements |
| NOS3 | Endothelial dysfunction | ASL overexpression in endothelial cells; NO production assays |
Argininosuccinic aciduria
Biallelic mutations in ASL cause argininosuccinic aciduria, an autosomal recessive urea cycle disorder. Patients present with hyperammonemia, elevated plasma argininosuccinate, and can develop neurocognitive deficits, hepatic fibrosis, and hypertension. The disease is typically managed with dietary protein restriction, arginine supplementation, and nitrogen-scavenging drugs, but long-term outcomes remain suboptimal.
Cancer metabolism
ASL plays a context-dependent role in cancer. In fumarate hydratase-deficient tumors, accumulated fumarate drives the reverse ASL reaction, consuming arginine and producing argininosuccinate, which may support tumor growth. In glioblastoma, ASL is involved in activating the mutant TERT promoter, contributing to telomerase activation and tumor immortality. Arginine metabolism is also a target in hepatocellular carcinoma and other cancers, where ASL expression can influence arginine availability [1,6].
Nitric oxide-related disorders
Because ASL supplies arginine for nitric oxide synthesis, altered ASL activity can affect vascular tone and immune function. Endothelial nitric oxide synthase (NOS3) depends on arginine from ASL, and dysregulation may contribute to hypertension and endothelial dysfunction. In inflammatory conditions, increased arginine consumption by ASL and other enzymes can limit NO production.
From argininosuccinate lyase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of ASL loss on urea cycle flux? | ASL knockout hepatocytes or mouse models; stable isotope tracing |
| How does ASL contribute to tumor growth? | ASL knockout cancer cell lines; xenograft models |
| Does a specific ASL mutation affect enzyme kinetics? | Point-mutation knock-in cell lines; recombinant protein assays |
| How does ASL acetylation regulate its activity? | Knock-in of acetylation-deficient or mimetic mutants; acetylation-specific antibodies |
| What is the role of ASL in TERT promoter activation? | ASL knockout glioblastoma cells; TERT promoter luciferase reporter |
| Can ASL be targeted for cancer therapy? | ASL overexpression and knockout models; drug sensitivity screens |
How to Study the argininosuccinate lyase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay (fumarate production) | ASL catalytic activity | Kinetic characterization of wild-type and mutant ASL |
| Stable isotope tracing | Metabolic flux through urea cycle and ASL | Quantifying forward and reverse ASL activity in cells |
| CRISPR knockout screens | Genes required for cell growth under specific conditions | Identifying ASL dependencies in cancer |
| Western blot | Protein expression and modification levels | Validating ASL knockout or acetylation status |
| Immunoprecipitation | Protein-protein interactions | Identifying ASL binding partners |
| Luciferase reporter assay | Transcriptional activity of TERT promoter | Studying ASL role in TERT activation |
| Mouse models | In vivo urea cycle function and disease phenotypes | Modeling argininosuccinic aciduria |
| iPSC-derived hepatocytes | Patient-specific metabolic phenotypes | Drug testing and disease modeling |
Enzymatic activity assays
Argininosuccinate lyase activity can be measured spectrophotometrically by monitoring the formation of fumarate at 240 nm or by quantifying arginine using colorimetric assays. Recombinant ASL protein or cell lysates can be used, and the reverse reaction can be assayed by measuring argininosuccinate formation from fumarate and arginine [7,8].
Metabolic flux analysis
Stable isotope tracing with 15N-labeled aspartate or 13C-labeled arginine can quantify flux through the urea cycle and ASL reaction in cells and tissues. This approach is particularly useful for studying reverse ASL activity in FH-deficient cancers.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that modulate ASL dependency or arginine auxotrophy. Such screens have been used to uncover metabolic vulnerabilities in cancers, including those related to arginine metabolism.
Proteomics and acetylation analysis
Mass spectrometry-based proteomics can identify post-translational modifications on ASL, such as acetylation. Immunoprecipitation followed by Western blotting with acetylation-specific antibodies can validate specific modification sites.
How CRISPR Can Be Used to Study GO:0004056 argininosuccinate lyase activity
Knockout
CRISPR knockout of ASL in cell lines or animal models abolishes argininosuccinate lyase activity, leading to accumulation of argininosuccinate and impaired urea cycle function. ASL knockout mice recapitulate features of argininosuccinic aciduria, including hyperammonemia and growth retardation. In cancer cells, ASL knockout can reduce proliferation under arginine-limited conditions and alter TERT promoter activity.
Point Mutation
Point mutations in ASL identified in patients can be introduced into cell lines using CRISPR prime editing or homology-directed repair. These models allow structure-function studies and assessment of residual enzyme activity. For example, missense mutations in the active site can be tested for their impact on catalysis and protein stability.
Knock-in
Knock-in of tagged ASL (e.g., FLAG or GFP) enables visualization and purification of the enzyme for interaction studies. Knock-in of patient-specific mutations into the endogenous ASL locus provides a more physiological model than overexpression. Such models are valuable for studying acetylation and other post-translational modifications.
Overexpression
Overexpression of wild-type or mutant ASL in cell lines can increase arginine production and alter metabolic flux. In cancer cells, ASL overexpression may promote growth under arginine deprivation or enhance TERT promoter activation. Overexpression models are also used to study the reverse reaction in FH-deficient cells.
How EDITGENE Supports argininosuccinate lyase activity Research
Researchers studying argininosuccinate lyase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling functional validation of ASL and its network.
Contact EDITGENE today to design your custom CRISPR model for argininosuccinate lyase activity research.
Frequently Asked Questions About argininosuccinate lyase activity
What is argininosuccinate lyase activity?
Argininosuccinate lyase activity (GO:0004056) is the enzymatic function that catalyzes the reversible cleavage of N-(L-arginino)succinate into fumarate and L-arginine. It is the fourth step of the urea cycle and the final step of arginine biosynthesis.
What gene encodes argininosuccinate lyase in humans?
The human ASL gene encodes argininosuccinate lyase. Mutations in ASL cause argininosuccinic aciduria.
What diseases are associated with argininosuccinate lyase deficiency?
ASL deficiency causes argininosuccinic aciduria, a urea cycle disorder with hyperammonemia, neurocognitive deficits, and liver disease. It has also been implicated in cancer metabolism, including glioblastoma and FH-deficient tumors [2,4,5].
How is argininosuccinate lyase activity measured?
It can be measured by enzymatic assays monitoring fumarate production at 240 nm or by quantifying arginine. Stable isotope tracing can measure flux through the reaction in cells [7,8].
What is the role of ASL in cancer?
ASL can support tumor growth by supplying arginine and, in FH-deficient cancers, by reversing its activity to consume arginine and produce argininosuccinate. In glioblastoma, ASL contributes to mutant TERT promoter activation [4,5].
What are the synonyms for argininosuccinate lyase activity?
Synonyms include argininosuccinase activity, arginine-succinate lyase activity, and omega-N-(L-arginino)succinate arginine-lyase activity.
What is the reaction catalyzed by argininosuccinate lyase?
The reaction is: N-(L-arginino)succinate = fumarate + L-arginine. It is reversible and belongs to the lyase class.
How is ASL regulated?
ASL is regulated by lysine acetylation, substrate availability, and in cancer, by oncogenic signaling. Its reverse activity is favored by fumarate accumulation [3,4].
What model systems are used to study ASL?
Common models include ASL knockout mice, patient-derived iPSCs, and CRISPR-engineered cell lines. Duck delta2-crystallin is a classic biochemical model [2,7,8].
Can CRISPR be used to study argininosuccinate lyase activity?
Yes. CRISPR knockout, point mutation, knock-in and overexpression models allow precise dissection of ASL function in urea cycle flux, cancer metabolism and TERT regulation [4,5].
Conclusion
Argininosuccinate lyase activity (GO:0004056) is a fundamental enzymatic function in nitrogen metabolism and arginine homeostasis. Its role extends from inherited urea cycle disorders to cancer metabolism and transcriptional regulation. The availability of CRISPR-based models and biochemical assays makes it an accessible target for mechanistic and translational research. Understanding ASL regulation and its moonlighting functions may reveal new therapeutic opportunities for metabolic diseases and cancer.
References
- 1. Du D et al.. 2022. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.. Acta Pharm Sin B 12(2):558-580 PMID: 35256934
- 2. Nagamani SC et al.. 2012. Argininosuccinate lyase deficiency.. Genet Med 14(5):501-7 PMID: 22241104
- 3. Zhao S et al.. 2010. Regulation of cellular metabolism by protein lysine acetylation.. Science 327(5968):1000-4 PMID: 20167786
- 4. Zheng L et al.. 2013. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells.. Cancer Metab 1(1):12 PMID: 24280230
- 5. Shi Z et al.. 2022. Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas.. Mol Cell 82(20):3919-3931.e7 PMID: 36270249
- 6. Chen CL et al.. 2021. Arginine Signaling and Cancer Metabolism.. Cancers (Basel) 13(14) PMID: 34298755
- 7. Lee HJ et al.. 1992. Biochemical characterization and kinetic analysis of duck delta-crystallin with endogenous argininosuccinate lyase activity.. Biochem J 283 ( Pt 2)(Pt 2):597-603 PMID: 1575702
- 8. Wu CY et al.. 1998. Chemical mechanism of the endogenous argininosuccinate lyase activity of duck lens delta2-crystallin.. Biochem J 333 ( Pt 2)(Pt 2):327-34 PMID: 9657972
